Bourne Lent Asset Management Inc Annovis Bio, Inc. Transaction History
Bourne Lent Asset Management Inc
- $263 Million
- Q3 2024
Shares
2 transactions
Others Institutions Holding ANVS
# of Institutions
46Shares Held
1.17MCall Options Held
229KPut Options Held
934K-
Vanguard Group Inc Valley Forge, PA380KShares$2.27 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il103KShares$612,0440.0% of portfolio
-
Black Rock Inc. New York, NY101KShares$600,2250.0% of portfolio
-
Geode Capital Management, LLC Boston, MA99.1KShares$590,7190.0% of portfolio
-
Group One Trading, L.P. Chicago, IL52.8KShares$314,4910.02% of portfolio
About Annovis Bio, Inc.
- Ticker ANVS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,163,920
- Market Cap $48.7M
- Description
- Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...